The mutated androgen receptor and its implications for the treatment of metastatic carcinoma of the prostate
- Author
- MIDDLEMAN, M. N1 ; LUSH, R. M1 ; FIGG, W. D1
[1] Clinical Pharmacokinetics Section, Clinical Pharmacology Branch, Clinical Oncology Program, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States - Conference title
- American College of Clinical Pharmacy. Annual Meeting
- Conference name
- American College of Clinical Pharmacy. Annual Meeting (Nashville, Tennessee 1996-08-04)
- Author (monograph)
- American College of Clinical Pharmacy, United States (Funder/Sponsor)
- Source
Pharmacotherapy. 1996, Vol 16, Num 3, pp 376-381 ; ref : 32 ref
- CODEN
- PHPYDQ
- ISSN
- 0277-0008
- Scientific domain
- Pharmacology drugs
- Publisher
- Pharmacotherapy, Boston, MA
- Publication country
- United States
- Document type
- Conference Paper
- Language
- English
- Keyword (fr)
- Androgène Antiandrogène Chimiothérapie Homme Hormone Mutation Prostate Récepteur biologique Résistance Traitement Tumeur maligne Appareil génital mâle pathologie Appareil urinaire pathologie Prostate pathologie
- Keyword (en)
- Androgen Antiandrogen Chemotherapy Human Hormone Mutation Prostate Biological receptor Resistance Treatment Malignant tumor Male genital diseases Urinary system disease Prostate disease
- Keyword (es)
- Andrógeno Antiandrógeno Quimioterapia Hombre Hormona Mutación Prostata Receptor biológico Resistencia Tratamiento Tumor maligno Aparato genital macho patología Aparato urinario patología Prostata patología
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02O Hormones. Endocrine system
- Discipline
- Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 3101578
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1002/j.1875-9114.1996.tb02967.x 
https://dx.doi.org/10.1002/j.1875-9114.1996.tb02967.x
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:34:\"10.1002\/j.1875-9114.1996.tb02967.x\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:108:\"The mutated androgen receptor and its implications for the treatment of metastatic carcinoma of the prostate\";s:9:\"\u0000*\u0000jtitle\";s:15:\"Pharmacotherapy\";s:9:\"\u0000*\u0000stitle\";s:15:\"Pharmacotherapy\";s:7:\"\u0000*\u0000date\";s:4:\"1996\";s:9:\"\u0000*\u0000volume\";s:2:\"16\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"376\";s:8:\"\u0000*\u0000epage\";s:3:\"381\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0277-0008\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"MIDDLEMAN\";s:10:\"\u0000*\u0000aufirst\";s:4:\"M. N\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:10:\"LUSH, R. M\";i:1;s:10:\"FIGG, W. D\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"PHPYDQ\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:53:\"American College of Clinical Pharmacy. Annual Meeting\";s:8:\"\u0000*\u0000title\";s:108:\"The mutated androgen receptor and its implications for the treatment of metastatic carcinoma of the prostate\";s:8:\"\u0000*\u0000place\";s:10:\"Boston, MA\";s:6:\"\u0000*\u0000pub\";s:15:\"Pharmacotherapy\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:34:\"10.1002\/j.1875-9114.1996.tb02967.x\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:108:\"The mutated androgen receptor and its implications for the treatment of metastatic carcinoma of the prostate\";s:9:\"\u0000*\u0000jtitle\";s:15:\"Pharmacotherapy\";s:9:\"\u0000*\u0000stitle\";s:15:\"Pharmacotherapy\";s:7:\"\u0000*\u0000date\";s:4:\"1996\";s:9:\"\u0000*\u0000volume\";s:2:\"16\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"376\";s:8:\"\u0000*\u0000epage\";s:3:\"381\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0277-0008\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"MIDDLEMAN\";s:10:\"\u0000*\u0000aufirst\";s:4:\"M. N\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:10:\"LUSH, R. M\";i:1;s:10:\"FIGG, W. D\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"PHPYDQ\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:53:\"American College of Clinical Pharmacy. Annual Meeting\";s:8:\"\u0000*\u0000title\";s:108:\"The mutated androgen receptor and its implications for the treatment of metastatic carcinoma of the prostate\";s:8:\"\u0000*\u0000place\";s:10:\"Boston, MA\";s:6:\"\u0000*\u0000pub\";s:15:\"Pharmacotherapy\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:34:\"10.1002\/j.1875-9114.1996.tb02967.x\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:34:\"10.1002\/j.1875-9114.1996.tb02967.x\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:108:\"The mutated androgen receptor and its implications for the treatment of metastatic carcinoma of the prostate\";s:9:\"\u0000*\u0000jtitle\";s:15:\"Pharmacotherapy\";s:9:\"\u0000*\u0000stitle\";s:15:\"Pharmacotherapy\";s:7:\"\u0000*\u0000date\";s:4:\"1996\";s:9:\"\u0000*\u0000volume\";s:2:\"16\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"376\";s:8:\"\u0000*\u0000epage\";s:3:\"381\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0277-0008\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"MIDDLEMAN\";s:10:\"\u0000*\u0000aufirst\";s:4:\"M. N\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:10:\"LUSH, R. M\";i:1;s:10:\"FIGG, W. D\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"PHPYDQ\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:53:\"American College of Clinical Pharmacy. Annual Meeting\";s:8:\"\u0000*\u0000title\";s:108:\"The mutated androgen receptor and its implications for the treatment of metastatic carcinoma of the prostate\";s:8:\"\u0000*\u0000place\";s:10:\"Boston, MA\";s:6:\"\u0000*\u0000pub\";s:15:\"Pharmacotherapy\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:34:\"10.1002\/j.1875-9114.1996.tb02967.x\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:108:\"The mutated androgen receptor and its implications for the treatment of metastatic carcinoma of the prostate\";s:9:\"\u0000*\u0000jtitle\";s:15:\"Pharmacotherapy\";s:9:\"\u0000*\u0000stitle\";s:15:\"Pharmacotherapy\";s:7:\"\u0000*\u0000date\";s:4:\"1996\";s:9:\"\u0000*\u0000volume\";s:2:\"16\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"376\";s:8:\"\u0000*\u0000epage\";s:3:\"381\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0277-0008\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"MIDDLEMAN\";s:10:\"\u0000*\u0000aufirst\";s:4:\"M. N\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:10:\"LUSH, R. M\";i:1;s:10:\"FIGG, W. D\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"PHPYDQ\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:53:\"American College of Clinical Pharmacy. Annual Meeting\";s:8:\"\u0000*\u0000title\";s:108:\"The mutated androgen receptor and its implications for the treatment of metastatic carcinoma of the prostate\";s:8:\"\u0000*\u0000place\";s:10:\"Boston, MA\";s:6:\"\u0000*\u0000pub\";s:15:\"Pharmacotherapy\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:34:\"10.1002\/j.1875-9114.1996.tb02967.x\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:108:\"The mutated androgen receptor and its implications for the treatment of metastatic carcinoma of the prostate\";s:9:\"\u0000*\u0000jtitle\";s:15:\"Pharmacotherapy\";s:9:\"\u0000*\u0000stitle\";s:15:\"Pharmacotherapy\";s:7:\"\u0000*\u0000date\";s:4:\"1996\";s:9:\"\u0000*\u0000volume\";s:2:\"16\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"376\";s:8:\"\u0000*\u0000epage\";s:3:\"381\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0277-0008\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"MIDDLEMAN\";s:10:\"\u0000*\u0000aufirst\";s:4:\"M. N\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:10:\"LUSH, R. M\";i:1;s:10:\"FIGG, W. D\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"PHPYDQ\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:53:\"American College of Clinical Pharmacy. Annual Meeting\";s:8:\"\u0000*\u0000title\";s:108:\"The mutated androgen receptor and its implications for the treatment of metastatic carcinoma of the prostate\";s:8:\"\u0000*\u0000place\";s:10:\"Boston, MA\";s:6:\"\u0000*\u0000pub\";s:15:\"Pharmacotherapy\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
